Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v13-EN | Version v4-FR | |
---|---|---|
Language | English | French |
Date Updated | 2017-04-13 | 2017-04-06 |
Drug Identification Number | 02439603 | 02439603 |
Brand name | VYVANSE | VYVANSE |
Common or Proper name | Lisdexamfetamine | Lisdexamfetamine |
Company Name | TAKEDA CANADA INC | TAKEDA CANADA INC |
Ingredients | LISDEXAMFETAMINE DIMESYLATE | LISDEXAMFETAMINE DIMESYLATE |
Strength(s) | 10MG | 10MG |
Dosage form(s) | CAPSULE | CAPSULE |
Route of administration | ORAL | ORAL |
Packaging size | Bottles of 100 capsules | Bottles of 100 capsules |
ATC code | N06BA | N06BA |
ATC description | PSYCHOSTIMULANTS AND NOOTROPICS | PSYCHOSTIMULANTS AND NOOTROPICS |
Reason for shortage | Demand increase for the drug. | Other (Please describe in comments) |
Anticipated start date | 2017-04-04 | 2017-04-04 |
Actual start date | 2017-04-04 | 2017-04-04 |
Estimated end date | 2017-04-11 | 2017-04-11 |
Actual end date | 2017-04-12 | |
Shortage status | Resolved | Actual shortage |
Tier 3 Status | No | No |
Company comments | Shire Distribution Center shortage only. Patient impact is not anticipated. | This is a Shire Distribution Center shortage only and is driven by increased demand; patient impact is not anticipated. |
Health Canada comments |